- Home
- APRE vs BLRX Comparison
APRE vs BLRX Comparison
Compare APRE & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- BLRX
- Stock Information
- Founded
- APRE 2006
- BLRX 2003
- Country
- APRE United States
- BLRX Israel
- Employees
- APRE N/A
- BLRX N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- BLRX Health Care
- Exchange
- APRE Nasdaq
- BLRX Nasdaq
- Market Cap
- APRE 13.5M
- BLRX 12.2M
- IPO Year
- APRE 2019
- BLRX 2011
- Fundamental
- Price
- APRE $1.80
- BLRX $2.94
- Analyst Decision
- APRE Strong Buy
- BLRX Buy
- Analyst Count
- APRE 2
- BLRX 2
- Target Price
- APRE $15.50
- BLRX $26.00
- AVG Volume (30 Days)
- APRE 21.0K
- BLRX 26.4K
- Earning Date
- APRE 05-13-2025
- BLRX 05-27-2025
- Dividend Yield
- APRE N/A
- BLRX N/A
- EPS Growth
- APRE N/A
- BLRX N/A
- EPS
- APRE N/A
- BLRX N/A
- Revenue
- APRE $1,502,581.00
- BLRX $28,940,000.00
- Revenue This Year
- APRE N/A
- BLRX N/A
- Revenue Next Year
- APRE N/A
- BLRX N/A
- P/E Ratio
- APRE N/A
- BLRX N/A
- Revenue Growth
- APRE 157.63
- BLRX 502.92
- 52 Week Low
- APRE $1.85
- BLRX $2.85
- 52 Week High
- APRE $6.70
- BLRX $35.60
- Technical
- Relative Strength Index (RSI)
- APRE 26.70
- BLRX 38.75
- Support Level
- APRE $1.85
- BLRX $3.01
- Resistance Level
- APRE $2.30
- BLRX $3.61
- Average True Range (ATR)
- APRE 0.16
- BLRX 0.21
- MACD
- APRE -0.01
- BLRX 0.02
- Stochastic Oscillator
- APRE 2.50
- BLRX 17.11
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.